In 2017, there have been substantial advances in our understanding of the immunological and endocrine mechanisms of disease progression in NAFLD, paving the way for novel therapeutic strategies.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease — meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73–84 (2016).
Wong, R. J. et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 148, 547–555 (2015).
Luedde, T., Kaplowitz, N. & Schwabe, R. F. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology,147 765–783.e4 (2014).
Guo, L. et al. Hepatic neuregulin 4 signaling defines an endocrine checkpoint for steatosis-to-NASH progression. J. Clin. Invest. 127, 4449–4461 (2017).
Jiang, J. et al. Circulating neuregulin 4 levels are inversely associated with subclinical cardiovascular disease in obese adults. Sci. Rep. 6, 36710 (2016).
Hart, K. M. et al. Type 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-β. Sci. Transl Med. 9, 396 (2017).
Majumdar, A. et al. Hepatic stem cells and transforming growth factor beta in hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 9, 530–538 (2012).
Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcioma. N. Engl. J. Med, 359, 378–390 (2008).
Shalapour, S. et al. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature 551, 340–345 (2017).
El-Khoueiry, A. B. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389, 2492–2502 (2017).
P.N.N. has served as a speaker, a consultant and an advisory board member for AbbVie, Boehringer Ingelheim, Gilead, Intercept, Janssen, Novartis, Novo Nordisk, Pharmaxis and Shire, and has received research funding from these organizations on behalf of the University of Birmingham, UK. R.S.K. has received research funding from the National Institute of Health Research.
About this article
Cite this article
Khan, R., Newsome, P. Novel insights into mechanisms of disease progression. Nat Rev Gastroenterol Hepatol 15, 71–72 (2018). https://doi.org/10.1038/nrgastro.2017.181
Bisphenol A exposure induces gut microbiota dysbiosis and consequent activation of gut-liver axis leading to hepatic steatosis in CD-1 mice
Environmental Pollution (2020)
Hepatic Autonomic Nervous System and Neurotrophic Factors Regulate the Pathogenesis and Progression of Non-alcoholic Fatty Liver Disease
Frontiers in Medicine (2020)
Mutual interaction between endoplasmic reticulum and mitochondria in nonalcoholic fatty liver disease
Lipids in Health and Disease (2020)
Free Radical Research (2020)
Medicinal Research Reviews (2019)